Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prev close 42.40 · opened flat. High/low 42.44 at 4:45 am ET, 42.38 at 4:00 am ET.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“In May 2024, we entered into a collaboration and license agreement with Sanofi, pursuant to which we granted Sanofi an exclusive license under certain intellectual property rights to commercialize losmapimod, an oral small molecule that we were developing for the treatment of FSHD outside of the United States and received an upfront payment of $80.0 million.”
FILING10-K0001193125-26-065197cik 0001680581disclosed by FULC
“In December 2019, we entered into a license agreement, which has been subsequently amended (as amended, the "Sanofi License Agreement"), with Sanofi, pursuant to which we have been granted an exclusive, worldwide, sublicensable, royalty-bearing license to develop and commercialize products using the licensed compounds and know-how for CFTR modulator therapies.”
FILING10-K0001628280-26-012996cik 0002036042disclosed by SION
“We license a number of technologies to form our antibody platform, and we license the PRO-XTEN ® platform from Sanofi and the siRNA technology from Alnylam.”
FILING10-K0001628280-26-010749cik 0001706431disclosed by VIR
“• ALDURAZYME: higher sales volume due to timing of order fulfillment to Sanofi as we recognize ALDURAZYME revenues when the product is released and control is transferred to Sanofi;”
FILING10-K0001048477-26-000004cik 0001048477disclosed by BMRN
“In May 2024, we completed a successful Merger and Separation with Sanofi for the 4 purchase of our INBRX-101 program for alpha-1 antitrypsin deficiency disorder.”
FILING10-K0002007919-26-000006cik 0002007919disclosed by INBX
“The Sanofi Agreement was terminated in June 2023, and Sanofi has no further reimbursement obligations following this termination.”
FILING10-K0001193125-26-071563cik 0001628171disclosed by RVMD
“Given the significant and growing contribution of AMVUTTRA to our total product revenues following regulatory approvals of AMVUTTRA for the treatment of ATTR-CM, our cost of goods sold, operating income and operating margin in 2025 were significantly impacted by the royalties we pay to Sanofi on global sales of AMVUTTRA under our TTR license agreements, and we expect this will continue in future years.”
FILING10-K0001628280-26-007497cik 0001178670disclosed by ALNY
“o In April 2023, we announced a collaboration with Sanofi who will sponsor and manage a Phase 1/2 trial of SARCLISA ® (isatuximab-irfc), an anti-cancer antibody, and dexamethasone in combination with evorpacept for the treatment of patients with relapsed or refractory multiple myeloma.”
FILING10-K0001193125-26-098454cik 0001810182disclosed by ALXO
“For example, we depend on licenses from Sanofi and MedRx for certain intellectual property relating to the development and commercialization of ALTO-101.”
FILING10-K0001999480-26-000002cik 0001999480disclosed by ANRO
“We also obtained worldwide exclusive rights to RLYB332 from Sanofi in 2022.”
FILING10-K0001628280-26-018261cik 0001739410disclosed by RLYB
“C o-exclusive licensing agreement with Novavax. The terms of the agreement include (i) a co-exclusive license to co- commercialize Novavax's current stand-alone adjuvanted COVID-19 vaccine worldwide (except in countries with existing Advance Purchase Agreements and in India, Japan, and South Korea, where Novavax has existing partnership agreements); (ii) a sole license to Novavax's adjuvanted COVID-19 vaccine for use in combination with Sanofi's flu vaccines; and (iii) a non- exclusive license to use the Matrix-M adjuvant in vaccine products. Novavax received an upfront payment of $ 500 million and could receive up to $ 700 million contingent on attainment of development, regulatory and commercialization milestones, representing up to $1.2 billion in total.”
FILING20-F0001628280-26-008403cik 0001121404
“In addition, under the collaboration agreement with Regeneron on monoclonal antibodies (see Note C.1.), Sanofi is entitled to receive an additional share of quarterly profits (capped at 10 % of Regeneron's share of quarterly profits until March 31, 2022, and thereafter at 20 % ), until Regeneron has paid 50 % of the cumulative development costs incurred by the parties to the alliance.”
FILING20-F0001628280-26-008403cik 0001121404
“We expect our sources of potential funding for the next several years to be derived primarily from sales of our commercialized products, with contributions from our existing collaborations, including royalties on sales of Leqvio by Novartis and on sales of Qfitlia by Sanofi, and any new strategic collaborations that we may enter in the future.”
FILING10-K0001628280-26-007497cik 0001178670disclosed by ALNY
“Exclusive licensing agreement with RadioMedix, Inc. and Orano Med for AlphaMedix (SAR447873), a late-stage project currently being evaluated for the treatment of adult patients with unresectable or metastatic progressive somatostatin- receptor expressing neuroendocrine tumors (NETs), a rare cancer. Under the licensing agreement, Sanofi will be responsible for the global commercialization of AlphaMedix, while Orano Med will be responsible for the manufacturing of AlphaMedix through its global industrial platform currently under development. Under the terms of the agreement, RadioMedix and Orano Med received an upfront payment of € 100 million and could receive up to € 220 million based on sales milestones, as well as being eligible for tiered sales-based royalties.”
FILING20-F0001628280-26-008403cik 0001121404
“Exclusive licensing agreement with RadioMedix, Inc. and Orano Med for AlphaMedix (SAR447873), a late-stage project currently being evaluated for the treatment of adult patients with unresectable or metastatic progressive somatostatin- receptor expressing neuroendocrine tumors (NETs), a rare cancer. Under the licensing agreement, Sanofi will be responsible for the global commercialization of AlphaMedix, while Orano Med will be responsible for the manufacturing of AlphaMedix through its global industrial platform currently under development. Under the terms of the agreement, RadioMedix and Orano Med received an upfront payment of € 100 million and could receive up to € 220 million based on sales milestones, as well as being eligible for tiered sales-based royalties.”
FILING20-F0001628280-26-008403cik 0001121404
“Sanofi will be responsible for delivering all supplies for current and future clinical trials and commercial production for Peripheral Products.”
FILING10-K0001714899-25-000066cik 0001714899disclosed by DNLI
“Exclusive licensing agreement with CORXEL Pharmaceuticals (CORXEL) to develop and commercialize aficamten in China, Hong Kong, Macao and Taiwan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy (HCM). Aficamten is an investigational, next-in-class selective small molecule cardiac myosin inhibitor discovered and developed globally by Cytokinetics. Sanofi has acquired CORXEL's rights relating to aficamten in China, Hong Kong, Macao and Taiwan for an undisclosed amount.”
FILING20-F0001628280-26-008403cik 0001121404
“Aficamten is an investigational, next-in-class selective small molecule cardiac myosin inhibitor discovered and developed globally by Cytokinetics. Sanofi has acquired CORXEL's rights relating to aficamten in China, Hong Kong, Macao and Taiwan for an undisclosed amount. Cytokinetics remains eligible to receive up to $ 150 million in development and commercial milestone payments from Sanofi as well as royalties in the low-to-high teens on future sales of aficamten in China, Hong Kong, Macao and Taiwan.”
FILING20-F0001628280-26-008403cik 0001121404
“Teva Pharmaceuticals (2023): collaboration agreement to co-develop and co-commercialize TEV'574 (duvakitug), for which positive Phase 2b clinical study results in patients with ulcerative colitis and Crohn's disease were announced on December 17, 2024;”
FILING20-F0001628280-26-008403cik 0001121404
“Adagene Inc., a company specializing in the discovery and development of antibody-based therapies (2022) : collaboration and exclusive license agreement;”
FILING20-F0001628280-26-008403cik 0001121404
“Denali Therapeutics Inc. (2018): collaboration agreement on the development of multiple molecules with the potential to treat a range of systemic inflammatory diseases such as ulcerative colitis.”
FILING20-F0001628280-26-008403cik 0001121404
“Kymera (2020): agreement to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases;”
FILING20-F0001628280-26-008403cik 0001121404
“Nurix Therapeutics (2020): collaboration to develop novel targeted protein degradation therapies;”
FILING20-F0001628280-26-008403cik 0001121404
“On January 2016, the Company entered into a research collaboration and licensing agreement with Sanofi to apply its proprietary technology to the development of multi-specific antibody formats engaging NK cells to kill tumor cells through the activating receptor NKp46.”
FILING20-F0001598599-26-000005cik 0001598599disclosed by IPHA
Watchlist prices, news filtered to it, and its next report on your desk.
Sanofi
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Manufacturing
Sanofi has 23 disclosed suppliers and 9 disclosed customers. Each one is named in an SEC filing, either Sanofi’s own annual report or the counterparty’s, and carries the sentence that discloses it.
SNY (Sanofi) has 23 disclosed suppliers and 9 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move, and a bundle sits past the rings until you open it. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: NRIX +2.09%, in the health bundle.